Patients taking Kerendia saw significant reduction in cardiovascular death and hospitalization and urgent visits for heart ...

The FDA expanded the indication for finerenone (Kerendia) in heart failure (HF), drug manufacturer Bayer announced.

Following priority review, the U.S. Food and Drug Administration approved Bayer's Kerendia (finerenone) for the treatment of ...

Heart failure, a condition where the heart doesn't pump blood efficiently, manifests through symptoms like shortness of ...

Wearables and telehealth are teaming up to transform chronic care. This connected model offers real-time data for proactive, ...

It’s as if sudden cardiac arrest is met with a resigned shrug: If it’s nearly impossible to predict and even harder to treat, ...

Learn about how the depiction of heart attacks in movies and television shows is incorrect and dangerous, and what signs you ...

Scientists have discovered that four health habits — which include sleep quality and nicotine use — were the most important ...

In a significant move, the U.S. Food and Drug Administration granted approval for Kerendia for patients with heart failure ...

A new system involving heart failure nurses at a Norfolk hospital has seen device alert response times plummet from weeks to ...

Bayer announced the FDA approved finerenone, a nonsteroidal selective mineralocorticoid receptor antagonist, for the ...

Approval of Kerendia was based on results from the Phase III FINEARTS-HF trial, which demonstrated statistically significant ...